Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
Basal cell carcinomas (BCCs) are the most common malignant tumors of the skin. Treatment of BCCs should be chosen according to clinical type, tumor size, and location. Methyl aminolevulinate (MAL) photodynamic therapy (PDT) has the potential to become a therapy with equal effectiveness to classical therapeutic modalities with an excellent cosmesis, but without complications like scar formation, requirement for grafts, need of repetitive treatments over longer time periods, or pigmentary changes. MAL is licensed in Europe, Australia, New Zealand, and Brazil for the treatment of actinic keratoses, Bowen's disease, and nodular and superficial BCC. Conclusions are drawn from extensive studies in past years using MAL-PDT for both nodular and superficial BCCs.
Szeimies
Rolf-Markus
RM
Department of Dermatology, Regensburg University Hospital, Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany. rolf-markus.szeimies@klinik.uni-regensburg.de
D000622:Aminolevulinic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D017319:Photosensitizing Agents; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid